By Pia Rivera
Trillium Therapeutics (NASDAQ:TRIL,TSX:TRIL) has presented new pharmacology data from its ongoing Phase 1 a/b trial of TTI-621 for patients with advanced hematologic malignancies.
As quoted in the press release:
The company presented the following new information from the trial:
Receptor occupancy increases with multiple infusions of TTI-621, conferring robust CD47 blockade on circulating